It’s not just a question of 95% immunity vs. 50% immunity (even if we were to take your arbitrary 50% number at face value). It’s also a question of how long w

It’s not just a question of 95% immunity vs. 50% immunity (even if we were to take your arbitrary 50% number at face value). It’s also a question of how long we expect the immunity to last for two-dose vs. one-dose, and where we expect to be in terms of virus spread and vaccine manufacturing and vaccination rates when that initial immunity runs out. These are complicated questions.